Cargando…
Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888147/ https://www.ncbi.nlm.nih.gov/pubmed/33596924 http://dx.doi.org/10.1186/s13045-021-01043-z |
| _version_ | 1783652111450374144 |
|---|---|
| author | Bolomsky, Arnold Vogler, Meike Köse, Murat Cem Heckman, Caroline A. Ehx, Grégory Ludwig, Heinz Caers, Jo |
| author_facet | Bolomsky, Arnold Vogler, Meike Köse, Murat Cem Heckman, Caroline A. Ehx, Grégory Ludwig, Heinz Caers, Jo |
| author_sort | Bolomsky, Arnold |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7888147 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78881472021-02-22 Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents Bolomsky, Arnold Vogler, Meike Köse, Murat Cem Heckman, Caroline A. Ehx, Grégory Ludwig, Heinz Caers, Jo J Hematol Oncol Correction BioMed Central 2021-02-17 /pmc/articles/PMC7888147/ /pubmed/33596924 http://dx.doi.org/10.1186/s13045-021-01043-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Bolomsky, Arnold Vogler, Meike Köse, Murat Cem Heckman, Caroline A. Ehx, Grégory Ludwig, Heinz Caers, Jo Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| title | Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| title_full | Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| title_fullStr | Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| title_full_unstemmed | Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| title_short | Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| title_sort | correction to: mcl-1 inhibitors, fast-lane development of a new class of anti-cancer agents |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888147/ https://www.ncbi.nlm.nih.gov/pubmed/33596924 http://dx.doi.org/10.1186/s13045-021-01043-z |
| work_keys_str_mv | AT bolomskyarnold correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents AT voglermeike correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents AT kosemuratcem correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents AT heckmancarolinea correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents AT ehxgregory correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents AT ludwigheinz correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents AT caersjo correctiontomcl1inhibitorsfastlanedevelopmentofanewclassofanticanceragents |